EVENTS | VIEW CALENDAR
This quarter has seen several contract research organizations (CROs) receiving kudos and awards for recent or ongoing efforts, both for individuals and the companies as a whole. On this awards/honors-oriented tour, we will be starting in North Carolina and then heading up the coast to New Jersey.
PPD honored for innovative OpenText use
WILMINGTON, N.C.—Pharmaceutical Product Development, LLC (PPD) was selected as the winner of the 2016 OpenText Elite Award for the Most Innovative Project in the Health Sciences Sector, which was announced at OpenText’s annual Enterprise World conference.
The award was presented for PPD’s use of OpenText to develop electronic trial master files for use in clinical trials. PPD developed a global, standardized process and taxonomy for managing data acquired or developed during a clinical trial. PPD’s version features a detailed folder structure, metadata and user groups that offer consistent structure, access and security across all studies for the company and its clients, with a single process employed globally for consistency in the conduct and content of clinical trials.
“Our clients benefit from our innovative use of portal technology to meet government compliance needs,” said Jay Dixon, senior vice president of global quality and compliance for PPD, regarding the award. “PPD is focused on ensuring that our compliance systems support efficient clinical trial processes to help our clients expedite their research programs to improve patients’ health.”
A nod to strategy
RALEIGH, N.C.—A little northward in Raleigh, INC Research Holdings Inc.’s Jean Chitwood, executive vice president of corporate strategy and development, was named in the 2016 PharmaVOICE 100 list. The list recognizes influential, inspirational leaders within the life-sciences industry, and has been released annually since 2005 to “celebrate individuals throughout the life-sciences industry who provide inspiration to their peers, colleagues and companies through their innovative and motivational approaches to addressing the industry’s myriad challenges,” according to an INC Research press release.
“Jean has imparted a true passion for strengthening INC by helping to formalize and engage our organization in the development and delivery of our business strategy to achieve our goals,” Jamie Macdonald, CEO of INC Research, commented in a statement. “Her strategic vision is a driving force within our company. She is always looking ahead to ensure INC is evolving with the environment and is in the best possible position to serve customers and patients both now and in the future. Jean has been integral in infusing a ‘Can do, I own it’ mindset into our corporate culture, so we are proud to see her contributions honored and can think of no one more deserving of this recognition.”
Chitwood has led several initiatives to boost the company’s relationship with sites and groups that heighten the voice of sites globally in an effort to improve trials for patients and clinicians, INC reported in a press release, in addition to being a key figure in integrating acquisitions. She has more than 25 years of experience in healthcare to her name, spanning academia, pharmaceutical and CRO sectors.
A quality quartet
ROCHELLE PARK, N.J.—A total of four 2016 CRO Leadership Awards were bestowed on full-service CRO TKL Research earlier this quarter from the annual Life Science Leader competition. Specifically, TKL was recognized in the areas of Capabilities, Compatibility, Expertise and Quality.
These awards, developed by Life Science Leader, are the result of independent research conducted by Industry Standard Reports, and this year, 65 CROs were assessed on 27 criteria by industry experts who had worked with them within the last 18 months.
“The CROs receiving an award this year are truly at the top of their class and are deserving of the recognition they receive,” commented Ed Miseta, executive editor for Life Science Leader. “Being a top performer in any of these categories shows a level of expertise and commitment to clinical trials and serving the needs of biopharmaceutical companies and their patients.”